Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06720545 · ClinicalTrials.gov registry record · NA

Cardiometabolic Risk Effects of Short-term Cessation of Neurostimulation Therapy

A NA study of Obstructive Sleep Apnea and Obstructive Sleep Apnea of Adult, sponsored by Columbia University.

Recruiting
Registry status
NA
Development phase
60
Enrollment target
1
Study location

NCT06720545 is a NA study of Obstructive Sleep Apnea and Obstructive Sleep Apnea of Adult that is actively recruiting participants, run by Columbia University. The registered enrollment target is 60 participants, below the 221-participant average among 155 other Obstructive Sleep Apnea trials with a reported enrollment target (73% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06720545, a NA study of Obstructive Sleep Apnea and Obstructive Sleep Apnea of Adult, is actively recruiting participants, sponsored by Columbia University.

RECRUITING
Registry status
NA
Development phase
60 participants
Enrollment target
1
Study location

Study Summary

Hypoglossal nerve stimulation (HGNS) is an implantable therapy that treats obstructive sleep apnea. The study will evaluate the effect of this treatment on cardiovascular and metabolism-related measures to see if it affects patients' risk of medical problems associated with obstructive sleep apnea (OSA).

Interventions

  • DEVICE No HGNS therapy (HGNS-off)

Study Locations (1)

New York

  • Columbia University Medical Center - New York

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2025-01-05
Est. Completion 2028-01
Phase NA

Sponsor

Columbia University

958 total trials

What the Registry Record Tells You About NCT06720545

The ClinicalTrials.gov registry entry for NCT06720545 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 221-participant average among 155 other Obstructive Sleep Apnea trials with a reported enrollment target (73% lower). The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Obstructive Sleep Apnea appearing as the primary indexed condition, and to 1 intervention - of which No HGNS therapy (HGNS-off) is the first listed.

NCT06720545 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT06720545 about?

NCT06720545 is a clinical study titled "Cardiometabolic Risk Effects of Short-term Cessation of Neurostimulation Therapy". Hypoglossal nerve stimulation (HGNS) is an implantable therapy that treats obstructive sleep apnea. The study will evaluate the effect of this treatment on cardiovascular and metabolism-related measures to see if it affects patients' risk of medical problems associated with obstructive sleep apnea ...

What is the current status of trial NCT06720545?

This trial is currently recruiting. It is a NA study. The enrollment target is 60 participants. The study started on 2025-01-05. Estimated completion is 2028-01.

What conditions does trial NCT06720545 study?

This clinical trial studies the following conditions: Obstructive Sleep Apnea, Obstructive Sleep Apnea of Adult.

What interventions are being tested in trial NCT06720545?

The interventions under investigation include: No HGNS therapy (HGNS-off) (DEVICE).

Who is sponsoring clinical trial NCT06720545?

This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06720545 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Obstructive Sleep Apnea

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.